Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02103179
Other study ID # k0113011-2013ECC
Secondary ID
Status Active, not recruiting
Phase N/A
First received March 31, 2014
Last updated March 31, 2014
Start date July 2006
Est. completion date September 2014

Study information

Verified date March 2014
Source First Affiliated Hospital, Sun Yat-Sen University
Contact n/a
Is FDA regulated No
Health authority China: Ministry of Science and Technology
Study type Observational

Clinical Trial Summary

The investigators study the VEGF signaling in ECC cell lines,patients and its mechanism in ECC growth, proliferation and apoptosis.


Description:

Several studies have documented the elevated expression of VEGF, VEGFR1 and VEGFR2 in cancer cell lines. Another study observed a sequential elevation of VEGF in low-grade dysplasia, high-grade dysplasia and early stage liver cancer. Clinical analyses have discovered the high expression of VEGF is correlated with tumor progression, vascular invasion, distal metastasis and poor prognosis. However, few studies have been conducted to investigate the VEGF signaling in ECC cells and its possible mechanism in regulating ECC growth.Therefore,we try to clarify the mechanism of VEGF signal in ECC growth,proliferation and apoptosis.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 20
Est. completion date September 2014
Est. primary completion date April 2014
Accepts healthy volunteers No
Gender Both
Age group 16 Years to 80 Years
Eligibility Inclusion Criteria:

1. Extrahepatic cholangiocarcinoma patients diagnosed through biopsy; two or more dynamic imagine with a diagnosis of Extrahepatic cholangiocarcinoma

2. Child-Pugh A or B

3. well preserved renal and hematopoietic Function

4. receive surgical therapy

5. achieve complete section accessed by contrast-enhanced CT

Exclusion Criteria:

1. incomplete section

2. remote metastasis

3. Child-Pugh C

4. combination with other hepatobiliary disease

5. suffer from other tumors concurrently or in last five years

Study Design

Observational Model: Case Control, Time Perspective: Retrospective


Related Conditions & MeSH terms


Intervention

Procedure:
surgical treatment
all the patients in the study must have been treated by the surgery at the first time and have been confirmed as 'complete section' by the post-surgery radiological image.

Locations

Country Name City State
China First Affiliated Hospital, Sun Yat-Sen University Guangzhou Guangdong

Sponsors (2)

Lead Sponsor Collaborator
First Affiliated Hospital, Sun Yat-Sen University Guangdong Province, Department of Science and Technology

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary the variation of the quantity of VEGF signal pathway genes in normal liver tissue,peri tumor,tumor and metastasis. the sections would be collected as previously described.Western blot,immunohistochemistry,PCR would be conducted to find out the variation between the normal liver tissue and tumor,tumor and meta(if have). the day when conducting surgery (day 1) No
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05009953 - Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer Phase 2
Recruiting NCT06101277 - Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG) N/A
Recruiting NCT05448183 - An Observational Real World Study on the Efficacy and Safety of Toripalimab Injection Combined With TACE in the Treatment of Extrahepatic Cholangiocarcinoma Phase 2
Active, not recruiting NCT04333927 - Adjuvant Immunotherapy Combined With Chemoradiation for Patients With High-risk reseCtable Extrahepatic chOlangiocaRcinoma and gallblaDder Cancer Phase 2
Recruiting NCT04561453 - Feasibility Study of Multi-Platform Profiling of Resected Biliary Tract Cancer
Not yet recruiting NCT06440993 - Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic Cholangiocarcinoma Phase 2
Recruiting NCT05519319 - Safety and Efficacy of PDT vs RFA vs PDT+RFA for the Treatment of Extrahepatic Cholangiocarcinoma N/A
Enrolling by invitation NCT05233293 - Spyglass+RFA Versus Cytobrush+RFA for Extrahepatic Cholangiocarcinoma N/A
Recruiting NCT05712356 - A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors Phase 2